Florida (U.S.A.) October 28, 2019: An announcement was made today by Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, that it has entered into a fully funded collaboration with one of the leading animal health companies.
Dyadic International, Inc. Image credit: Official site
Under the terms of the agreement, Dyadic will apply its proprietary and patented C1 gene expression platform to express three different types of proteins to be evaluated by our collaborator for its potential use in their research and commercial projects.
Dyadic International is developing a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1.
Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.
"Today's announcement further evidences the broad applications of our C1 technology platform for both human and animal health needs. This collaboration in the animal health markets reinforces our momentum in another high growth sector, companion and farm animal health. The regulatory pathway in animal health, compared to human trials for biologics approvals, is much shorter with the cost of goods being a much more critical issue. We believe that our C1 technology platform uniquely addresses these issues and provides us with another potential catalyst for growth," said CEO Mark Emalfarb.
"We are excited to announce an additional animal health-related research agreement...to help speed the development, lower the cost and improve the performance of biologic vaccines and drugs for both farm and companion animals...increasing interest from both our previously announced collaborators as well as other bio-pharmaceutical companies involved in the animal health sector," commented Matthew Jones, Dyadic's Chief Commercial Officer.